Scorr-Insert
X

Find Immunology Drugs in Phase II Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Epinephrine

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            The presentation will highlight promising results for ARS Pharmaceuticals' lead asset, ARS-1 which results in bioequivalent exposure to epinephrine injection given once and twice.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Clobetasol Propionate

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 22, 2020

            Details:

            Study conducted in OLP patients with the 20?g dose of Rivelin-CLO demonstrated a statistically significant improvement in ulcer area, and continued to show improvement through the end of 4 weeks.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMVT-1401

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: SVB Leerink

            Deal Size: $139.4 million Upfront Cash: Undisclosed

            Deal Type: Public Offering April 16, 2020

            Details:

            Company closed its previously announced underwritten public offering of 9,613,365 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,253,917.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Telitacicept

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 15, 2020

            Details:

            US FDA granted Fast Track designation for RC18, for the treatment of systemic lupus erythematosus (SLE). RC18 shows statistically significant improvement for patients at multiple doses.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Belumodsil

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            Details:

            Based on the feedback from the FDA, the Company believes the proposed data package will be sufficient to support a submission of KD025 for the treatment of patients with cGVHD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OSE-127

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Laboratoires Servier

            Deal Size: $21.4 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 17, 2020

            Details:

            In December 2016, OSE Immunotherapeutics granted Servier a two-step option agreement to acquire the exclusive worldwide license to develop and commercialize OSE-127.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Belumodsil

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 23, 2020

            Details:

            KD025 has been well tolerated and has already demonstrated high response rates in patients with severe and complex cGVHD after a median of five months of follow-up.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabidiol

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Kalytera Therapeutics

            Deal Size: $0.3 million Upfront Cash: Undisclosed

            Deal Type: Agreement February 07, 2020

            Details:

            Salzman Group has provided certain services in connection with the Kalytera's programs for the development of cannabidiol for treatment of graft versus host disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MaaT013

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Symbiosis Pharmaceutical Services LTD

            Deal Size: $19.5 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing February 05, 2020

            Details:

            The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KZR-616

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cowen

            Deal Size: $56.8 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 04, 2020

            Details:

            Kezar intends to use the net proceeds from the offering primarily to fund the research and development of its product candidates, acquire or license products or technologies.

            PharmaCompass